Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BYSI 
BeyondSpring Inc (BYSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BYSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.25
1 Year Target Price $1.25
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.59% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 98.77M USD | Price to earnings Ratio - | 1Y Target Price 1.25 |
Price to earnings Ratio - | 1Y Target Price 1.25 | ||
Volume (30-day avg) 1 | Beta 0.08 | 52 Weeks Range 0.98 - 3.44 | Updated Date 06/30/2025 |
52 Weeks Range 0.98 - 3.44 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.51% | Return on Equity (TTM) -310.48% |
Valuation
Trailing PE - | Forward PE 10.54 | Enterprise Value 89182331 | Price to Sales(TTM) 31.22 |
Enterprise Value 89182331 | Price to Sales(TTM) 31.22 | ||
Enterprise Value to Revenue 26.53 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 40316300 | Shares Floating 29803840 |
Shares Outstanding 40316300 | Shares Floating 29803840 | ||
Percent Insiders 15.26 | Percent Institutions 13.11 |
Analyst Ratings
Rating 1 | Target Price 1.25 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BeyondSpring Inc
Company Overview
History and Background
BeyondSpring Inc. is a global biopharmaceutical company focused on developing innovative cancer therapies. Founded in 2010, BeyondSpring's initial focus was on developing Plinabulin, its lead asset, and has evolved to include a pipeline of oncology drugs.
Core Business Areas
- Oncology Drug Development: Focuses on researching, developing, and commercializing cancer therapies. Their main product is Plinabulin. Focuses on drug discovery.
Leadership and Structure
Dr. Lan Huang is the co-founder, CEO and Chairperson. The company operates with a management team focused on clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Plinabulin: A selective immuno-oncology agent that targets GEF-H1/microtubule dynamics. It is approved in the US and China for chemotherapy-induced neutropenia (CIN). Competitors for CIN include Amgen's Neulasta and Neupogen, and Coherus BioSciences' Udenyca. Market share is still developing as the drug is relatively new to the market.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Oncology is a significant area of focus with high unmet needs.
Positioning
BeyondSpring is positioned as an innovator in the oncology space with a unique mechanism of action for Plinabulin. Its competitive advantage lies in its potential to address unmet needs in CIN and potentially other cancer indications.
Total Addressable Market (TAM)
The TAM for CIN and broader oncology applications is estimated to be in the billions of dollars. BeyondSpring is positioned to capture a portion of this market through successful commercialization and expansion of Plinabulin's indications.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action
- Approved in US and China
- Strong Intellectual Property
- Experienced Management Team
Weaknesses
- Limited Commercial Infrastructure
- Reliance on Single Product
- High Cash Burn Rate
- Market Acceptance of New Drug
Opportunities
- Expansion of Plinabulin Indications
- Partnerships and Collaborations
- Geographic Expansion
- Positive Clinical Trial Results
Threats
- Competition from Established Therapies
- Regulatory Hurdles
- Clinical Trial Failures
- Funding Challenges
Competitors and Market Share
Key Competitors
- AMGN
- COHR
- SCLX
Competitive Landscape
BeyondSpring faces strong competition from established players with larger commercial infrastructure. Its advantage lies in its novel mechanism of action, but market penetration will be challenging.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by clinical trial progress and regulatory approvals.
Future Projections: Future growth depends on successful commercialization of Plinabulin and expansion into new indications. Analyst estimates vary widely.
Recent Initiatives: Focus on commercial launch of Plinabulin, continued clinical trials, and exploring partnerships.
Summary
BeyondSpring is a development-stage biopharmaceutical company with an approved product, Plinabulin, in the US and China. While the approval is a significant achievement, the company faces challenges in commercializing the product and competing with larger pharmaceutical companies. The company has a high cash burn rate and relies heavily on the success of a single product. It needs to successfully expand Plinabulin's indications to be successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeyondSpring Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2017-03-09 | Co-Founder, Chairman & CEO Dr. Lan Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://beyondspringpharma.com |
Full time employees 40 | Website https://beyondspringpharma.com | ||
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.